PRCXI Bioinformatics Co., Ltd.
PrivateLast Round
Series A
Extension
Dec 31, 2025
Total Funding Raised
$13.75M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
PRCXI Bioinformatics Co., Ltd. operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series A round in July 2025.
PRCXI Bioinformatics Co., Ltd. is a life science automation company that provides laboratory automation equipment, consumables, and integrated solutions for biopharmaceutical, clinical diagnostic, and research laboratories.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Workflow Automation, Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PRCXI Bioinformatics Co., Ltd. Comparables
Compare PRCXI Bioinformatics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NAYO Biotechnology | 91% | |
| Flow Robotics A/S | 81% | |
| Danaher | 77% |
For institutional investors. Book with your work email.
PRCXI Bioinformatics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 31, 2025 | ||||
| Series A | Jul 1, 2025 | ||||
| Early Funding | Apr 8, 2024 | ||||
| Early Funding | Jan 2, 2024 | ||||
| Early Funding | Oct 1, 2023 |
For institutional investors. Book with your work email.
PRCXI Bioinformatics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CCIC Capital | Series A Extension |
| CITIC Construction Investment Capital Management | Series A |
| Suzhou Wuzhong Financial Holdings Group | Early Funding |
| Qiming Venture Partners | Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 28, 2026
Open roles increased to 20, 2.3x the trailing average.
- Aug 20, 2026
Monthly visitors increased 145% MoM.
For institutional investors. Book with your work email.
PRCXI Bioinformatics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PRCXI Bioinformatics Co., Ltd.'s valuation, stock price, and market status.
Is PRCXI Bioinformatics Co., Ltd. a public or private company?
PRCXI Bioinformatics Co., Ltd. is a private company.
What is the current stock price of PRCXI Bioinformatics Co., Ltd.?
PRCXI Bioinformatics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks PRCXI Bioinformatics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PRCXI Bioinformatics Co., Ltd. worth (valuation)?
Valuation information for PRCXI Bioinformatics Co., Ltd. is not publicly available.
Can I buy PRCXI Bioinformatics Co., Ltd. stock?
PRCXI Bioinformatics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PRCXI Bioinformatics Co., Ltd.'s last funding round?
PRCXI Bioinformatics Co., Ltd.'s most recent funding round was Series A Extension on December 31, 2025.
Who are the main investors in PRCXI Bioinformatics Co., Ltd.?
Key investors in PRCXI Bioinformatics Co., Ltd. include CITIC Construction Investment Capital Management.
Will PRCXI Bioinformatics Co., Ltd. IPO soon?
No public IPO plans have been announced for PRCXI Bioinformatics Co., Ltd..
How can I track PRCXI Bioinformatics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in PRCXI Bioinformatics Co., Ltd.'s shares on secondary markets.